1 / 25

END2.4 - Diabetes mellitus 4 Biochemistry of diabetic complications

END2.4 - Diabetes mellitus 4 Biochemistry of diabetic complications. ©Dr S Nussey. Hyperglycaemic hypothesis. DM is associated with 2 types of complication - Macrovascular - i.e. accelerated atherosclerosis Microvascular - affecting predominantly the eye, nerves and kidneys

shae
Télécharger la présentation

END2.4 - Diabetes mellitus 4 Biochemistry of diabetic complications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. END2.4 - Diabetes mellitus 4Biochemistry of diabetic complications ©Dr S Nussey

  2. Hyperglycaemic hypothesis • DM is associated with 2 types of complication - • Macrovascular - i.e. accelerated atherosclerosis • Microvascular - affecting predominantly the eye, nerves and kidneys • Microvascular complications are specific to diabetes • Although subject to genetic influences, microvascular complications are related to the duration and quality of glucose control

  3. Protein structure • Protein structure determines function • Changes in structure alter function • In these examples, lens crystal is rendered opaque and collagen inflexible Cataract Cheiro- arthropathy

  4. Cell metabolism • Alterations in cellular metabolism affect cell function • In this example, disturbances in axoplasmic transport affect nerve function Neuropathic ulcer on heel

  5. Extracellular matrix structural changes • Deposition of interstitial materials may affect function • In this case, glomerular function is severely affected leading to renal failure Normal Diabetic

  6. Cellular proliferation • Changes in cell signalling may lead to cell division • In this example, proliferation of new blood vessels in the retina lead to blindness Proliferative retinopathy

  7. Vascular function • Changes may lead to an increase in vascular permeability • In this example, production of exudates or haemorrhages in the retina lead to blindness

  8. Four major hypotheses* • Increased activity of aldose reductase (sorbitol pathway) • Formation of reactive oxygen species (‘free-radicals’) • Increased production of advanced glycation end-products (AGE) • Activation of protein kinase C (PKC) *Note - these are potentially linked in complex ways

  9. Principle of hyperglycaemic ‘memory’ • Experimentally, the damage done to tissue during periods of hyperglycaemia is ‘remembered’. • Thus, after a period of poor diabetic control complications occur at an accelerated rate even though subsequent glycaemic control is excellent.

  10. Q - Why is an understanding of the biochemistry of diabetic complications important? A - Because it leads to therapeutic opportunities.

  11. Sorbitol pathway • Increased fructose leads to: osmotic changes; non-enzymic fructosylation and AGE (via 3-deoxyglucasone) • Decreased NADPH/NADP+ leads to: alteration in redox state(decreased ability to deal with oxidative stress); increased activity of pentose phosphate shunt (PPP) • Increased NADH/NAD+ leads to: increased activity of PPP • Increased triose phosphate intermediates leads to increased second messenger diacylglycerol (DAG) and, thus, Protein Kinase C activity. • Increase PKC activity leads to a wide variety of changes (see later) • Arachidonate in DAG may be a substrate for the synthesis of eicosanoids including prostaglandins, prostacyclins, thromboxanes and leukotrienes all of which have potent vascular (and other) actions

  12. Pentose phosphate pathway • Important in the generation of: • NADPH as source of reducing power in biosynthesis • ribose phosphate to synthesize RNA, DNA, FAD, CoA • The red loop indicates the reversibility via transketolase and transaldolase and the intermediates fructose 6-phosphate and glyceraldehyde 3-phosphate thus linking the PPP with glycolysis

  13. Aldose reductase inhibitors • Good results in animal models • Less good in human trials • Why? • AR not expressed in all tissues affected by DM e.g. endothelial cell • most trials short-term but complications accrue over many years • other pathways more important?

  14. Free radicals in DM - ‘Oxidative stress’ • Increased production e.g. by auto-oxidation of glucose, superoxide production from mitochondrial oxidation of NADH to NAD+ • Decreased clearance via action of catalase or glutathione peroxidase. Regeneration of reduced glutathione requires NADPH, levels of which are decreased (in tissues containing aldose reductase)

  15. ‘Carbonyl stress’ • The idea of carbonyl stress arose from the recognition that not all damaging processes required oxidation. • Carbonyl products (e.g. methylglyoxal and 3-deoxyglucasone) are obtained non-oxidatively via the PPP and inhibit glutathione reductase. • These may form AGE or, in the presence of membrane lipids, form lipid dialdehydes that form glycoxidated adducts. • Note that AR has apparently deleterious effects at 1 but potentially beneficially ones at 2 and 3

  16. AGE • Maillard reaction ‘browning’ of food described in 1912 • Non-enzymatic glycation of amines

  17. AGE

  18. AGE CML Pentosidine MOLD

  19. AGE • Receptors for AGE include: macrophage scavenger receptor for AGE (types I and II); oligosaccharyl transferase-48; 80-K H phosphoprotein and galectin • The scavenger receptors belong to the immunoglobulin superfamily • Expressed on wide variety of cells and expression is increased in animal models of DM • AGE-RAGE interactions are important in a number of inflammatory conditions • They also occur in atherosclerosis and this draws both micro- and macro- vascular complications together pathophysiologically

  20. AGE directed therapies • Aminoguanidine an inhibitor of AGE formation has good results in animal nephropathy models • Undergoing phase III clinical trials • Others include phenacylthiazolium

  21. Protein kinase C

  22. PKC X = processes inhibited by LY333531

  23. PKC directed therapy • LY333531- an orally active inhibitor of PKC-bII isoform- good results in animal models of both retinal and renal disease

  24. Overview

More Related